As per the terms of the agreement, Nuokang is expected to get license to register, market and distribute Dianatal Obstetric Gel in Mainland China, Hong Kong, Macao and Taiwan.
Additionally Nuokang is also expected to introduce the product in Hong Kong, Macao and Taiwan by early 2011. In mainland China, Nuokang expects that product registration could take up to 18 months.
Dianatal Obstetric Gel is a product developed in Switzerland to reduce trauma associated with vaginal childbirth, in the Greater China region.
In clinical trials Dianatal showed that application of the product by first time mothers could reduce the risk of perineal injury associated with vaginal childbirth, and could also reduce the duration of the second stage of labor by up to 30%.
Nuokang is currently marketing Dianatal Obstetric Gel in Switzerland, Germany, UK and Central Europe with GSK and Sandoz Pharmaceuticals.
Baizhong Xue, chairman and CEO of Nuokang, said: “We are pleased to work with HCB to register and market Dianatal Obstetric Gel in the Greater China region. The market potential and the strategic fit make this an exciting opportunity for Nuokang.”
Andreas Schaub, founder and CEO of HCB, said: “Overall, our clinical experience and patient feedback confirms that Dianatal Obstetric Gel makes a positive contribution to the experience and outcome of childbirth. Together with Nuokang, we are happy to make this contribution in the Greater China region.”